Clinical Trial Update: DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing DCb (docetaxel/carboplatin) to EC-D (epirubicin/cyclophosphamide followed by docetaxel) as neoadjuvant chemotherapy for triple-negative …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• DCb (docetaxel/carboplatin) (docetaxel + carboplatin)
• EC-D (epirubicin/cyclophosphamide followed by docetaxel) (epirubicin + cyclophosphamide + docetaxel)

Snippet

Sponsor: Guangdong Provincial People's Hospital | Conditions: Triple-Negative Breast Cancer | Phase 2 | Status: COMPLETED